Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Tony Gordon, Murali Prahalad


Genesis Genetics has appointed Tony Gordon to be laboratory director for its UK operations and vice president of its US operations. In his new roles, Gordon will sign off on all patient reports in the UK and will help expand the company's testing operations in the country.

Gordon joins Detroit-based Genesis Genetics from BlueGnome. Genesis Genetics relies on BlueGnome's 24sure array comparative genomic hybridization platform in its preimplantation genetic diagnostic services, according to its website.

Murali Prahalad has been named president and CEO of Epic Sciences, a La Jolla, Calif.-based company developing microfluidic chip-based tests that isolate and characterize circulating tumor cells.

Prahalad joins Epic from Life Technologies, where he was vice president of corporate strategy. He also served as vice president of business development at Sequenom and as an analyst for Gemini Consulting in Tokyo.

In addition to English, Prahalad speaks Japanese, French, and Kannada, a language spoken in India, Epic said.

Prahalad holds a PhD in biochemistry and molecular pharmacology from Harvard University, and a BSc in cellular and molecular biology from the University of Michigan.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.